Thrivent Financial for Lutherans Buys Shares of 30,333 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Thrivent Financial for Lutherans purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 30,333 shares of the company's stock, valued at approximately $679,000.

A number of other institutional investors also recently modified their holdings of NTLA. Vanguard Group Inc. grew its position in Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company's stock valued at $250,168,000 after purchasing an additional 746,263 shares in the last quarter. ARK Investment Management LLC grew its holdings in shares of Intellia Therapeutics by 5.5% in the 2nd quarter. ARK Investment Management LLC now owns 11,595,789 shares of the company's stock valued at $259,514,000 after acquiring an additional 606,507 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company's stock valued at $51,494,000 after acquiring an additional 371,189 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Intellia Therapeutics during the fourth quarter worth about $9,086,000. Finally, Pinnacle Associates Ltd. acquired a new position in Intellia Therapeutics during the first quarter valued at approximately $7,035,000. 88.77% of the stock is currently owned by institutional investors.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company's stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.00% of the stock is currently owned by insiders.

Intellia Therapeutics Price Performance

Intellia Therapeutics stock traded up $0.05 during midday trading on Tuesday, hitting $17.89. The company's stock had a trading volume of 2,093,052 shares, compared to its average volume of 1,524,781. The company has a 50-day moving average price of $21.65 and a two-hundred day moving average price of $23.34. Intellia Therapeutics, Inc. has a 1-year low of $17.43 and a 1-year high of $34.87. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -3.34 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to analysts' expectations of $19.68 million. During the same period last year, the firm posted ($1.40) EPS. The business's revenue for the quarter was down 48.5% on a year-over-year basis. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -5.22 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on NTLA. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Intellia Therapeutics in a report on Monday, June 24th. Truist Financial reaffirmed a "buy" rating and issued a $120.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Evercore ISI upgraded Intellia Therapeutics to a "strong-buy" rating in a report on Friday, August 9th. Royal Bank of Canada restated an "outperform" rating and issued a $54.00 price objective on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Finally, Stifel Nicolaus decreased their target price on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a report on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $61.77.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.